Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- 26 Jul 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
- 06 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016.
- 07 Jun 2016 Results (n=274) assessing sequencing of bevacizumab and lomustine in subjects with first recurrence of a glioblastoma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.